Population pharmacokinetics of tigecycline: a systematic review

CC Zhou, F Huang, JM Zhang… - Drug Design …, 2023 - Taylor & Francis
Although tigecycline is widely used in clinical practice, its efficiency and optimal dosage
regimens remain controversial. The purpose of this article was to help guide tigecycline …

[HTML][HTML] All roads lead to rome: Enhancing the probability of target attainment with different pharmacokinetic/pharmacodynamic modelling approaches

K Khalid, K Rox - Antibiotics, 2023 - mdpi.com
In light of rising antimicrobial resistance and a decreasing number of antibiotics with novel
modes of action, it is of utmost importance to accelerate development of novel treatment …

Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review

D Echeverria-Esnal, L Sorli… - Expert Review of Anti …, 2023 - Taylor & Francis
Introduction Enterococcus faecium is a commensal microorganism that can cause infections
such as bacteremia. Incidence of ampicillin-resistant and vancomycin-susceptible E …

Population pharmacokinetics of antibacterial agents in the older population: a literature review

HX Liu, BH Tang, J van den Anker, GX Hao… - Expert review of …, 2024 - Taylor & Francis
Introduction Older individuals face an elevated risk of developing bacterial infections. The
optimal use of antibacterial agents in this population is challenging because of age-related …

[HTML][HTML] New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties

A Lombardi, L Alagna, E Palomba… - Transplant …, 2024 - frontierspartnerships.org
Antimicrobial resistance is a growing global health problem, and it is especially relevant
among liver transplant recipients where infections, particularly when caused by …

[HTML][HTML] Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling

W Su, S Song, J Liu, H Yu, B Feng, Y Wu… - Frontiers in …, 2024 - frontiersin.org
Background: Due to the heterogeneity of critically ill patients, the pharmacokinetics of
tigecycline are unclear, and the optimal dosing strategy is controversial. Methods: A single …

A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

K Sun, F Peng, K Xu, Y Liu, X Zhou, N Shang… - Frontiers in Public …, 2024 - frontiersin.org
Background This study aimed to explore the risk factors for failed treatment of carbapenem-
resistant Acinetobacter baumannii ventilator-associated pneumonia (CRAB-VAP) with …

[HTML][HTML] Population pharmacokinetics of tigecycline in critically ill patients

X Luo, S Wang, D Li, J Wen, N Sun… - Frontiers in Pharmacology, 2023 - frontiersin.org
Objective: In critically ill patients, the change of pathophysiological status may affect the
pharmacokinetic (PK) process of drugs. The purpose of this study was to develop a PK …

[HTML][HTML] Pharmacokinetic/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting

X Yang, L Jin, X Luo, S An, M Wang… - Therapeutic Drug …, 2022 - journals.lww.com
Background: This study aimed to investigate the pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of various tigecycline dosing regimens in real-world patients with …